Researchers discovered that inhibiting NOD2 improved the chemotherapeutic sensitization of nonsmall-cell lung cancer (NSCLC) to paclitaxel in Lewis lung carcinoma (LLC) tumor-bearing mice [41]. This evidence concerns the gene NOD2 and neoplasm.